Bio-heart has finally revealed the data of its seismic trial. It shows that Myocell Myoblast clinical cell therapy is good way to improve heart problems like cardiac devices and congested heart diseases. Researchers also say that the treatment is a safe one. The research was conducted with 26 patients receiving Myocell therapy, against 14 patients in control group. All of them were patients of heart disease, receiving standard medical treatment. Six month of trial revealed that almost 84% of the patient were improved.

Patrick Serruys, of the research team, says that the MyoCell Myoblast clinical cell therapy, has shown interesting results. The main concern is safety, however the study shows positive trends in clinical benefit, he further added.
Source: Pharmaceutical Business Review